All In Biotech

Drug Trial Radar · NCT06569056

A Trial of HRS-8427 in the Treatment of Adults With Complicated Urinary Tract Infection, Including Acute Pyelonephritis

A Multi-center, Randomized, Double-blind, Active Controlled, Parallel Groups, Phase III Study to Evaluate the Efficacy and Safety of HRS-8427 in the Treatment of Adults With Complicated Urinary Tract Infection, Including Acute Pyelonephritis

Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 579 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

579

Actual

Start

Sep 25, 2024

Primary completion

Sep 1, 2026

Study completion Sep 1, 2026

Sponsor

Sponsor type
Industry
First posted
Aug 23, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of HRS-8427 in patients with complicated urinary tract infection, including acute pyelonephritis.

Conditions

  • Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)

Interventions

  • HRS-8427Drug

    Dosing frequency: for 7-14 days; dose adjustments of subjects with reduced function include reduced doses

  • Imipenem and Cilastatin SodiumDrug

    Dosing frequency: for 7-14 days; dose adjustments of subjects with reduced function include reduced doses

  • HRS-8427 placeboDrug

    Dosing frequency: for 7-14 days; dose adjustments of subjects with reduced function include reduced doses

  • Imipenem and Cilastatin Sodium placeboDrug

    Dosing frequency: for 7-14 days; dose adjustments of subjects with reduced function include reduced doses

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at Test of Cure (TOC)Time frame: Test of cure (TOC; 7 days after end of treatment [EOT], equivalent to Study Day 14 to 21)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Huashan Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.